Details of the Drug-Related molecule(s) Interaction Atlas

V-102862 Drug Info

CO 102862; UNII-0KN11H90GF; 181144-66-1; V-102862; CHEMBL287833; 0KN11H90GF; 4-(4-fluorophenoxy)benzaldehyde semicarbazone; (E)-2-(4-(4-fluorophenoxy)benz-ylidene)hydrazinecarboxamide; V102862; 2-(4-(4-Fluorophenoxy)benzylidene)hydrazinecarboxamide; 2-((4-(4-Fluorophenoxy)phenyl)methylene)hydrazinecarboxamide; CO-102862; 2-[[4-(4-Fluorophenoxy)phenyl]methylene]hydrazinecarboxamide; Hydrazinecarboxamide, 2-((4-(4-fluorophenoxy)phenyl)methylene)-; CHEBI:92156; MolPort-022-863-701; BDBM50141073; AKOS016004881; NCGC00167807-01

Cross-matching ID

PubChem CID

9816959

ChEBI ID

CHEBI:92156

CAS Number

CAS 181144-66-1

TTD Drug ID

DMR2EUV

General Information of Drug (ID: DMR2EUV)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.4 (SCN4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lanperisone	DM4EGPN	Musculoskeletal disorder	FA00-FC0Z	Phase 3	[3]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[4]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[5]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[5]
BW-202W92	DMFKXMT	Discovery agent	N.A.	Investigative	[4]
CCNCSSKWCRDHSRCC	DMBGHTW	Discovery agent	N.A.	Investigative	[6]
CCNCSSKWCRAHSRCC	DM96YR2	Discovery agent	N.A.	Investigative	[6]
CCACSSKWCRDHSRCC	DMSE20Y	Discovery agent	N.A.	Investigative	[6]
CCNCASKWCRDHSRCC	DMRFA5O	Discovery agent	N.A.	Investigative	[6]
ZNCCNCSSKWCRDHSRCC	DMY2V37	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN-402	DMR69CG	Osteoarthritis	FA00-FA05	Phase 2	[7]
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[8]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[9]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[9]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[9]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[10]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[9]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[11]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[9]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.4 (SCN4A)	TT84DRB	SCN4A_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52.
2	Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40.
3	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
4	Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707.
5	Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8.
6	Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706.
7	Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
8	Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
9	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
12	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)